Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Generation Bio (Nasdaq:GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has granted equity awards to a new employee under its 2025 Inducement Stock Incentive Plan. The grant includes non-statutory stock options for 128,600 shares at an exercise price of $0.32 per share.

The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and 6.25% vesting quarterly thereafter, contingent on continued employment.

News Market Reaction

+6.94%

1 alert

+6.94% News Effect

On the day this news was published, GBIO gained 6.94%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company’s 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The employee received non-statutory stock options stock options to purchase an aggregate of 128,600 shares of the company’s common stock. The options have an exercise price of $0.32 per share, which is equal to the closing price of the company’s common stock on the date of grant. The options have a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and 6.25% of the shares underlying the option vesting quarterly thereafter, subject to the employee’s continued service with the company through the vesting dates. The inducement grant is subject to the terms and conditions of award agreements and the company’s 2025 Inducement Stock Incentive Plan.

About Generation Bio   
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit www.generationbio.com.

Investors and Media Contact  
Maren Killackey  
Generation Bio  
mkillackey@generationbio.com  
857-371-4638

FAQ

What equity awards did Generation Bio (GBIO) grant to its new employee in July 2025?

Generation Bio granted 128,600 non-statutory stock options at an exercise price of $0.32 per share to one new employee.

What is the vesting schedule for Generation Bio's July 2025 inducement grant?

The options vest over 4 years, with 25% vesting after the first year and 6.25% vesting quarterly thereafter, subject to continued employment.

What is the exercise price for Generation Bio's July 2025 inducement stock options?

The exercise price is $0.32 per share, equal to the closing price of GBIO's common stock on the grant date of July 1, 2025.

How long is the term of Generation Bio's July 2025 inducement stock options?

The stock options have a 10-year term.